BCAX at a glance
Bicara Therapeutics Inc. (BCAX, SEC CIK 2023658) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Bicara Therapeutics Inc. (BCAX) shares worth $329.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cohlhepp Ryan on September 8, 2026 of 14,058 shares at $22.77 per share.
- In the last 90 days, BCAX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($401K) on Form 4, a net sale of $401K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$401K
- 13F holders
- 25 funds
- $329.5M · −3 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No explicit new risk factor identified versus the 10-K; filing presents existing risks without a change statement
- Financial: $442.3 million cash, equivalents and marketable securities projected to fund operations into first half of 2029
- Regulatory: BIOSECURE Act restrictions could impair supply from Chinese biotechnology partners, with prohibitions expected in 2027 at earliest
- Operational: Reliance on WuXi Biologics for ongoing clinical supply creates concentration risk amid China-U.S. geopolitical tensions
- Clinical: Ficerafusp alfa’s Phase 2/3 FORTIFI-HN01 trial faces enrollment, safety and regulatory approval uncertainty
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales or other revenue generated
- Net loss $71.2M vs $36.3M YoY, operating expenses $75.7M vs $40.7M
- R&D highest spending area: $56.5M vs $33.0M, driven by FORTIFI-HN01 and FORTIFI-FLEX
- Cash, equivalents and marketable securities $442.3M; operating cash use $137.8M vs $82.9M
- February offering added $161.8M; funding expected into first half of 2029, additional capital needed thereafter
AI summary of the BCAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Bicara Therapeutics’ financial results for the quarter ended September 30, 2026
- Business updates accompany the quarterly results, with substantive details in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FORTIFI-HN01 achieved substantial enrollment, supporting topline interim results in mid-2027 for first-line HPV-negative HNSCC
- Cash, equivalents and marketable securities reached $442.3 million, funding operations into the first half of 2029 under current plans
Item 1.01: Entry into a Material Definitive Agreement
- New 35,090-square-foot Boston headquarters at 10 St. James Avenue
- Base rent $105,279 monthly, payable nine months after commencement
Item EX-99.1: Item EX-99.1
- Leadership succession: Ryan Cohlhepp becomes CEO January 1, 2027, while Claire Mazumdar transitions to Vice Chair and Strategic Advisor
- FORTIFI-HN01 pivotal trial expected substantially enrolled by year-end, targeting interim topline results in mid-2027
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and business updates announced for quarter ended June 30, 2026
- Full results and operational details available in Exhibit 99.1 press release
AI summaries of BCAX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BCAX
Don't miss the next BCAX filing
- Alerts as it files. A push when BCAX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BCAX, by share count.
- Ask anything. An AI agent that reads every BCAX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cohlhepp Ryan | M | Sep 8, 2026 | 17,500 | $3.79 |
| Cohlhepp Ryan | Sell | Sep 8, 2026 | 14,058 | $22.77 |
| Cohlhepp Ryan | Sell | Sep 8, 2026 | 3,442 | $23.43 |
| Cohlhepp Ryan | M | Sep 8, 2026 | 17,500 | - |
| Larson Jennifer | A | Aug 12, 2026 | 285,000 | - |
| Hyep Ivan | Sell | Aug 10, 2026 | 12,500 | $27.97 |
| Hyep Ivan | M | Aug 10, 2026 | 12,500 | $3.79 |
| Hyep Ivan | M | Aug 10, 2026 | 12,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$39.9M | -$82.4M | -$155.6M |
| Net Income | - | -$68.0M | -$137.9M |
| Balance Sheet | |||
| Total Assets | $234.0M | $510.0M | $431.0M |
| Equity | -$148.8M | $491.9M | $401.5M |
| ROE | - | -13.8% | -34.4% |
| Per Share | |||
| EPS | $-89.61 | $-4.05 | $-2.52 |
| Cash Flow | |||
| Operating CF | -$45.6M | -$74.8M | -$106.8M |
| CapEx | $586K | $71K | $280K |
Source: XBRL data in Bicara Therapeutics Inc. (BCAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BCAX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $329.5M |
| Q2 2026 | 28 | $561.5M |
| Q1 2026 | 27 | $311.3M |
| Q4 2025 | 22 | $240.0M |
| Q3 2025 | 21 | $208.5M |
| Q2 2025 | 21 | $120.3M |
| Q1 2025 | 18 | $100.6M |
| Q4 2024 | 10 | $87.9M |
- Citadel Advisors LLC+818.9K (+388%)
- Franklin Resources+713.2K (+37%)
- Two Sigma Investments+362.8K (+778%)
- Millennium Management+328.8K (+125%)
- Dimensional Fund Advisors+195.2K (+42%)
- D.E. Shaw & Co−371.8K (-75%)
- JPMorgan Chase & Co−299.5K (-29%)
- Goldman Sachs Group−115.1K (-22%)
- Morgan Stanley−63.8K (-22%)
- Wells Fargo & Co−26.4K (-66%)
- FMR LLC (Fidelity)−1.89M
- Raymond James Financial−12.0K
- Prudential Financial−7.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 172 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BCAX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BCAX SEC filings: frequently asked questions
Are BCAX insiders buying or selling?
In the last 90 days, Bicara Therapeutics Inc. (BCAX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $400,716 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BCAX stock?
As of September 30, 2026, the largest Bicara Therapeutics Inc. (BCAX) holders among the 13F filers tracked by SignalX were BlackRock ($73.4 million), Vanguard Capital Management LLC ($41.2 million), State Street Corp ($38.3 million), T. Rowe Price Group ($35.7 million), Franklin Resources ($23.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did BCAX report in its latest 8-K?
Bicara Therapeutics Inc. (BCAX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Bicara Therapeutics’ financial results for the quarter ended September 30, 2026.
What are the latest BCAX SEC filings?
Bicara Therapeutics Inc. (BCAX) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on September 10, 2026.
What is BCAX's SEC CIK number?
Bicara Therapeutics Inc. (BCAX)'s SEC Central Index Key (CIK) is 2023658. EDGAR lists every BCAX filing under that number.
Ask anything about BCAX
The research agent reads BCAX's filings, financials, insider trades and 13F holders, then answers with sources.